Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Clinical significance of loss of heterozygosity for M6P/IGF2R in patients with primary hepatocellular carcinoma
Ist Teil von
World journal of gastroenterology : WJG, 2008-03, Vol.14 (9), p.1394-1398
Ort / Verlag
United States: Department of Radiation Ontology,The Catholic University of Korea,School of Medicine,Seoul,Korea%Department of Radiation Oncology,Gyeongsang National University,Postgraduate School of Medicine,Gyeongsang Institute of Health Sciences,Jinju 660-702,Korea%Department of Surgery,Gyeongsang National University,Postgraduate School of Medicine,Jinju 660-702,Korea%Department of Radiation Ontology,Duke University Medical Center,Durham,NC,United States
Erscheinungsjahr
2008
Quelle
MEDLINE
Beschreibungen/Notizen
AIM:To investigate the relationship between loss of heterozygosity (LOH) for mannose 6-phosphate/insulin- like growth factor 2 receptor (M6P/IGF2R) and the outcomes for primary HCC patients treated with partial hepatectomy.
METHODS: The LOH for M6P/IGF2R in primary HCC patients was assessed using six different gene-specific nucleotide polymorphisms. The patients studied were enrolled to undergo partial hepatectomy.
RESULTS: M6P/IGF2R was found to be polymorphic in 73.3% (22/30) of the patients, and of these patients, 50.0% (11/22) had tumors showing LOH in M6P/IGF2R. Loss of heterozygosity in M6P/IGF2R was associated with significant reductions in the two year overall survival rate (24.9% vs 65.5%; P = 0.04) and the disease-free survival rate (17.8% vs 59.3%; P = 0.03).
CONCLUSION: These results show M6P/IGF2R LOH predicts poor clinical outcomes in surgically resected primary HCC patients.